Home › B-Cell Lymphoma › NCT06792734

Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

Phase 1A/1B Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* must be age ≥18 years
* must have a diagnosis of relapsed or refractory mature B cell lymphoma
* must have measurable disease per response evaluation criteria in lymphoma (Lugano classification)
* must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2
* must have a predicted life expectancy of ≥3 months
* must agree to use adequate birth control throughout their participation and for 90 days following the last dose of BTM-3566

Exclusion Criteria:

* has primary CNS lymphoma
* has ongoing toxicities from prior anti-cancer treatment \> Grade 1
* has symptomatic or uncontrolled neurologic disease (brain metastases, leptomeningeal disease, or spinal cord compression) not definitively treated with surgery or radiation
* has received any anti-cancer therapy (including radiation of curative intent) \<28 days prior to administration of BTM-3566
* has current second malignancy at other sites (exceptions: non-melanomatous skin cancer, adequately treated in situ carcinoma, or indolent prostate cancer under observation).
* is pregnant or breastfeeding

About the study

The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are:

What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)?

Participants will:

Take BTM-3566 in 14-day periods with 7 days of dosing followed by 7 days of no dosing Visit the clinic regularly for checkups and tests Keep a diary of their dosing and weight

What is being tested

• BTM-3566 (drug)

Sponsor: Bantam Pharmaceuticals · Participants: 24 · Started: Feb 14, 2025

Contact the study team

• Lori McDermott · Phone: 1-646-598-4823

Official record on ClinicalTrials.gov — NCT06792734

Locations in the U.S.

Conditions

• B-Cell Lymphoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.